For Citizens Bank Park more information and to

For surveys about citizens bank park more information at citizens bank park in shows and to register please go to About APX Inc.APX is the leading infrastructure provider for environmental and energy marketsin renewable energy and greenhouse gases, including carbon commodities. APXbusiness services include the APX Environmental Management Account, a completesuite of solutions for environmental asset and risk management in the new carboneconomy. More than 1300 global firms trust APX to create, track, manage, andretire environmental commodities across all renewable energy markets in NorthAmerica and greenhouse gas markets worldwide. APX also provides technology,strategic consulting, and expert operational services to assist wholesale powermarket participants reduce costs and improve performance in power scheduling,settlement, market operations, system operations support, and demand responseprograms APX is a privately held company.

Inc.Reiner Musier, 617.699.0929 (mobile)408.517.2100 (office)Chief Marketing Copyright Business Wire 2009 and citizens bank park . LONDON & WHITEHOUSE STATION, N.J.--(Business Wire)--AstraZeneca and Merck & Co., Inc bar at citizens bank park . today announced a collaboration to research anovel combination anticancer regimen composed of two investigational compounds,MK-2206 from Merck and AZD6244 (ARRY-886*) from AstraZeneca by citizens bank park . Preclinical evidence indicates that combined administration of these compoundscould enhance their anticancer properties citizen ball park . This is the first time that two largepharmaceutical companies have established a collaboration to evaluate thepotential for combining candidate molecules at such an early stage ofdevelopment. The collaboration will more quickly advance a potentially promisinganticancer treatment.

In general, such combinations would only be studied whenone or both of the drugs has entered late-stage development or receivedmarketing approval around citizens bank park . Under the terms of the agreement, AstraZeneca and Merck will work together toevaluate co-administration of the compounds in a Phase I clinical trial for thetreatment of solid cancer tumors at citizens bank park in . All development costs will be shared jointly.Following the Phase I trial, the companies will consider opportunities forfurther clinical development bar at citizens bank park . Each candidate is designed to inhibit a protein known to be abnormally activatedin human cancers . In preclinical studies, AZD6244 has been shown to affect MEK(Mitogen-activated protein kinase 1), an important signal that promotes cancercell growth and survival. AZD6244 has completed Phase I evaluation,demonstrating proof of mechanism, and several Phase II monotherapy studies,which showed evidence of clinical activity. It is currently in Phase II clinicaltrials in a range of tumor types.